SCHEMBL4056418

SCHEMBL4056418

Clc1ccc(CCc2nc3ncc(-c4ccco4)cc3[nH]2)cc1Cl

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NOS1 P29475 4/20 0.41
NOS2 P35228 4/20 0.41
NOS3 P29474 3/20 0.41
ADORA2A P29274 2/20 0.38
ADORA1 P30542 2/20 0.38
LMNA P02545 2/20 0.35
MAPT P10636 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
PDE10A Q9Y233 2/20 0.35
CLK1 P49759 3/20 0.35
CLK2 P49760 3/20 0.35
DYRK1A Q13627 3/20 0.35
CLK4 Q9HAZ1 3/20 0.35
DYRK1B Q9Y463 3/20 0.35
BRAF P15056 1/20 0.34
WDR5 P61964 1/20 0.33
PTGES O14684 1/20 0.33
CLK3 P49761 1/20 0.33
MEN1 O00255 2/20 0.33
KMT2A Q03164 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4057770 0.90 RNASEH1 (0.37) NOS1NOS2NOS3ADORA2AADORA1
SCHEMBL4053237 0.89 NOS3 (0.42) NOS1NOS2NOS3ADORA2AADORA1
SCHEMBL4058842 0.87 MEN1 (0.41) NOS1NOS2NOS3ADORA2AADORA1
SCHEMBL4060650 0.85 NOS3 (0.49) NOS1NOS2NOS3ADORA2AADORA1
SCHEMBL4057778 0.85 NOS3 (0.44) NOS1NOS2NOS3ADORA2AADORA1
SCHEMBL4058313 0.85 NOS1 (0.44) NOS1NOS2NOS3ADORA2AADORA1
SCHEMBL4054880 0.85 NOS3 (0.42) NOS1NOS2NOS3ADORA2AMAPT
SCHEMBL4055225 0.84 NOS1 (0.42) NOS1NOS2NOS3ADORA2AMAPT
SCHEMBL4052352 0.83 NOS3 (0.54) NOS1NOS2NOS3ADORA2AADORA1
SCHEMBL13608664 0.83 ADORA2A (0.38) ADORA2AADORA1LMNAMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7622479-B2 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-11-24 US disclosed
US-20050101647-A1 Bicyclic derivative, its production and use TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-05-12 US disclosed
EP-1460067-A1 BICYCLIC DERIVATIVE, PROCESS FOR PRODUCING THE SAME, AND USE Takeda Chemical Industries, Ltd. (JP) 2004-09-22 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050101647-A1 Bicyclic derivative, its production and use ABL1, SRC, PTK2B NOS1 879/4885NOS2 1019/4885NOS3 907/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.